amino acid substitution raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-04 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
That same year, Alex B. Novikoff from the University of Vermont visited de Duve's laboratory, and, using electron microscopy, successfully produced the first visual evidence of the lysosome organelle. Using a staining method for acid phosphatase, de Duve and Novikoff further confirmed the location of the hydrolytic enzymes (acid hydrolases) of lysosomes.
=== EC 1.8.4 With a disulfide as acceptor === EC 1.8.4.1: glutathione—homocystine transhydrogenase EC 1.8.4.2: protein-disulfide reductase (glutathione) EC 1.8.4.3: glutathione—CoA-glutathione transhydrogenase EC 1.8.4.4: glutathione—cystine transhydrogenase EC 1.8.4.5: Now EC 1.8.4.13, L-methionine (S)-S-oxide reductase and EC 1.8.4.14, L-methionine (R)-S-oxide reductase EC 1.8.4.6: due to EC 1.8.4.11, peptide-methionine (S)-S-oxide reductase EC 1.8.4.7: enzyme-thiol transhydrogenase (glutathione-disulfide) EC 1.8.4.8: phosphoadenylyl-sulfate reductase (thioredoxin) EC 1.8.4.9: adenylyl-sulfate reductase (glutathione) EC 1.8.4.10: adenylyl-sulfate reductase (thioredoxin) EC 1.8.4.11: peptide-methionine (S)-S-oxide reductase EC 1.8.4.12: peptide-methionine (R)-S-oxide reductase EC 1.8.4.13: L-methionine (S)-S-oxide reductase EC 1.8.4.14: L-methionine (R)-S-oxide reductase EC 1.8.4.15: protein dithiol oxidoreductase (disulfide-forming) EC 1.8.4.16: thioredoxin:protein disulfide reductase
== Diagnosis == Craniocervical instability is usually diagnosed through neuro-anatomical measurement using radiography. Digital Motion X-ray is considered the most accurate method. Upright magnetic resonance imaging, supine magnetic resonance imaging, CT scan, and flexion and extension x-rays may also be used but are far less accurate and have a much higher potential for false negatives. The measurements to diagnose craniocervical instability are:
The flow of currents within an axon can be described quantitatively by cable theory and its elaborations, such as the compartmental model. Cable theory was developed in 1855 by Lord Kelvin to model the transatlantic telegraph cable and was shown to be relevant to neurons by Hodgkin and Rushton in 1946. In simple cable theory, the neuron is treated as an electrically passive, perfectly cylindrical transmission cable, which can be described by a partial differential equation.
Sources: en.wikipedia.org
The system studied – the part of the patient that is the object of the examination (blood plasma, pituitary gland, skin, kidney, whole body) The component – the specific part or process that is of interest in the system studied (glucose, hormone secretion, bacteria, urine excretion) The kind-of-property - (amount-of-substance concentration, secretion rate, number, volume) An SI unit or WHO where relevant – (for measurable properties, i.e. differential or rational [not ordinal] quantities). These statements are ordered in a fixed syntax:
=== Menopausal hormone therapy === CPA is used at low doses in menopausal hormone therapy in combination with an estrogen to provide endometrial protection and treat menopausal symptoms. It is used in menopausal hormone therapy under the brand name Climen, which is a sequential preparation that contains 2 mg estradiol valerate and 1 mg CPA. Climen was the first product for use in menopausal hormone therapy containing CPA to be marketed. It is available in more than 40 countries.
=== Diabetes-like symptoms === While sirolimus inhibition of mTORC1 appears to mediate the drug's benefits, it also inhibits mTORC2, which results in diabetes-like symptoms. This includes decreased glucose tolerance and insensitivity to insulin. Sirolimus treatment may additionally increase the risk of type 2 diabetes. In mouse studies, these symptoms can be avoided through the use of alternate dosing regimens or analogs such as everolimus or temsirolimus.
=== GLMA: Health Professionals Advancing LGBTQ Equality === GLMA: Health Professionals Advancing LGBTQ Equality is the world's largest and oldest LGBTQ healthcare professionals association founded in 1981. It is also formerly known as the Gay and Lesbian Medical Association. GLMA provides resources along with educational programs to help healthcare professionals gain the knowledge and skills in giving appropriate care to LGBTQ patients whilst hosting conferences and workshops to foster the environment for discussion of the latest research or emerging issues in the field. They also conduct LGBTQ centered research to identify the disparities and health needs to publish guidelines and inform about evidence-based healthcare practices and policies to LGBTQ health.
=== Australia === Australia has documented 10 cases of healthcare-acquired CJD (iatrogenic or ICJD). Five of the deaths resulted after the patients, who were in treatment either for infertility or short stature, were treated using contaminated pituitary extract hormone but no new cases have been noted since 1991. The other five deaths occurred due to dura mater grafting procedures that were performed during brain surgery, in which the covering of the brain is repaired. There have been no other ICJD deaths documented in Australia due to transmission during healthcare procedures.
Sources: en.wikipedia.org
Levacetylmethadol (INN), levomethadyl acetate (USAN), OrLAAM (trade name) or levo-α-acetylmethadol (LAAM) is a synthetic opioid similar in structure to methadone. It has a long duration of action due to its active metabolites.
=== Pharmacokinetics === Methaqualone reaches peak plasma concentrations within a few hours of administration. Its elimination half-life ranges between 20 and 60 hours, contributing to its sedative effects and potential for accumulation with repeated dosing.
The endocrine system is a network of glands and organs located throughout the body. Along with the nervous system, it makes the neuroendocrine system, which controls and regulates many of the body's functions. Endocrine glands are ductless glands of the endocrine system that secrete their products, hormones, directly into the blood. The major glands of the endocrine system include the pineal gland, pituitary gland, pancreas, ovaries, testicles, thyroid gland, parathyroid gland, hypothalamus and adrenal glands. The hypothalamus and pituitary glands are neuroendocrine organs.
== History of electric slow cookers == Slow cookers achieved popularity in the United States during the 1940s, when many women began to work outside the home. They could start dinner cooking in the morning before going to work and finish preparing the meal in the evening when they came home. The Naxon Utilities Corporation of Chicago, under the leadership of electrical engineer Irving Naxon (born Irving Nachumsohn), developed the Naxon Beanery All-Purpose Cooker for the purposes of cooking a bean meal. Naxon was inspired by a story related by his mother, how in her native Lithuanian town his grandmother made a traditional Jewish stew called cholent, which took several hours to cook in an oven. A 1950 advertisement shows a slow cooker called the "Simmer Crock" made by the Industrial Radiant Heat Corporation of Gladstone, New Jersey. The Rival Company of Kansas City, Missouri, bought Naxon in 1970, acquiring Naxon's 1940 patent for the bean simmer cooker. Rival asked inventor Alex MacMaster, from Boonville, Missouri, to develop Naxon's bean cooker into a large scale production model that could cook an entire family meal, going further than just cooking a bean meal. Alex also designed and produced the mass-production machines for Rival's manufacturing line of the Crock-Pot. The cooker was then reintroduced under the trademark "Crock-Pot" in 1971. In 1974, Rival introduced removable stoneware inserts, making the appliance easier to clean. As of 2016, the Crock-Pot brand belongs to Newell Brands.
Protolichesterinic acid is primarily isolated from Cetraria islandica through modern chromatographic techniques. A standard method employs a two-step process, beginning with petroleum ether extraction in a Soxhlet extractor followed by crystallization. Initial purification uses size-exclusion chromatography with Sephadex LH20 (a size-exclusion resin) in a dichloromethane-acetone system to separate protolichesterinic acid from other paraconic acids. Final purification employs centrifugal partition chromatography using a solvent system of n-heptane, ethyl acetate, and acetonitrile, achieving over 99% purity with yields exceeding 65%. While the compound exhibits instability in acetonitrile, converting to lichesterinic acid, it remains stable when stored in ethanol. Quantitative analysis is typically performed using reversed-phase high-performance liquid chromatography (HPLC) with UV detection. A validated method using a LiChrosorb RP-8 column achieves separation within 3.7 minutes and demonstrates excellent linearity (0.125–2.5 μg/ml) with a detection limit of 1 nanogram. The method's reliability is confirmed by its high precision (0.78% relative standard deviation) and good recovery rate (90%), making it suitable for accurate determination of protolichesterinic acid content in biological samples.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.